14 May 2020 - Approval based on positive ECHELON-2 phase 3 trial results demonstrating superior progression-free survival and overall survival with Adcetris plus CHP chemotherapy.

Seattle Genetics today announced that its collaborator Takeda has received approval from the European Commission to extend the current conditional marketing authorisation for Adcetris (brentuximab vedotin) to include treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma, in combination with CHP (cyclophosphamide, doxorubicin, prednisone).

The decision follows a positive opinion from the CHMP on 27 March 2020.